Prophylactic cefazolin in amnioinfusions administered for meconium-stained amniotic fluid

Area of Science:

• Obstetrics and Gynecology
• Infectious Diseases

Background:

• Meconium-stained amniotic fluid (MSAF) increases the risk of maternal and neonatal infections.
• Amnioinfusion is a procedure used to dilute meconium in the amniotic fluid.

Purpose of the Study:

• To evaluate if amnioinfusion with an antibiotic solution reduces clinical chorioamnionitis and puerperal endometritis in patients with MSAF.
• To assess the impact of prophylactic antibiotic amnioinfusion on neonatal infection rates.

Main Methods:

• A randomized controlled trial involving pregnant patients at 36 weeks' gestation or greater with MSAF.
• Participants received either cefazolin in normal saline or normal saline alone via amnioinfusion.
• Maternal infection (chorioamnionitis, endometritis) and neonatal infection rates were compared between groups.

Main Results:

• No significant difference in the incidence of clinical chorioamnionitis (7.8% vs. 8.6%) between the cefazolin and control groups.
• Endometritis rates (2.4% vs. 3.5%) and aggregate intrauterine infection rates (10.0% vs. 11.8%) were also not significantly different.
• Neonatal infection rates, both suspected (17.8% vs. 21.5%) and culture-proven (0.0% vs. 2.2%), showed no significant reduction with cefazolin amnioinfusion.

Conclusions:

• Prophylactic cefazolin in amnioinfusions does not significantly decrease maternal or neonatal infection rates in MSAF pregnancies.
• The findings suggest that antibiotic amnioinfusion is not effective in preventing infections associated with MSAF.
• Further research may be needed to explore alternative strategies for infection prevention in these cases.